Pharma EBITDA Margins Slide 126bps Amid Freight Surge

Market Trends

Research notes received by FinBizNet today highlight a sharp divergence within the Indian market, concentrating on two distinct industries: Pharmaceuticals and Oil and Gas Refining and Marketing. In the pharmaceutical sector, the data reveals a structural challenge where robust domestic sales growth is being offset by significant margin compression in export markets. Simultaneously, the oil and gas segment presents a complex picture of deep marketing losses for marketers coexisting with elevated global refining margins.

Pharmaceuticals

The overall read from the research notes received today regarding the pharmaceutical industry is neutral. The data indicates that while domestic pharmaceutical sales are maintaining double-digit growth driven by chronic therapy pricing power and new launches, the sector faces headwinds in its international operations. Specifically, the generic semaglutide market is experiencing supply disruptions due to quality failures, leading to shifts toward tirzepatide. This dynamic is reshaping the landscape for major players who had previously relied on GLP-1 demand.

The specific figures behind this read show a clear tension between volume growth and profitability. According to the notes, the sector is projected to see sales growth of +17% YoY in Q2FY27E, with an EBITDA growth of +12% YoY. However, the EBITDA margin change is estimated at -126 bps YoY, indicating a falling trend. This compression is largely attributed to US pricing erosion and freight cost spikes, which have risen by +93% YoY. Despite these export challenges, the India Pharma Market (IPM) continues to perform well, with volume growth at +12.1% YoY in July 2026 and sales value reaching ₹232.7bn in August 2026. The broader IPM growth for July/August 2026 stands at +13% YoY, showing a rising trend.

The mechanism driving these numbers involves a shift in therapeutic focus. Chronic therapies, particularly cardiac and anti-diabetic drugs, are driving secondary sales growth of over 15% in August 2026. Meanwhile, the GLP-1 market dynamics are evolving, with tirzepatide capturing approximately 62% of the market share as semaglutide demand softens. The CRDMO segment is delivering strong performance, with 18% revenue and 34% EBITDA growth. On the risk side, generic semaglutide supply disruptions from API-linked impurity failures are affecting Dr Reddy's Labs and Torrent Pharma. Additionally, potential Section 232 tariff changes following a White House budget office review scheduled for April 2027 pose a policy risk. The absence of gRevlimid sales and competitive pressure on products like gJynarque and gMyrbetriq further impact top-line performance.

The listed companies discussed in these notes reflect these mixed conditions. Alkem Laboratories Ltd maintains a neutral view for 2QFY27. Sun Pharmaceutical Industries Limited has a constructive read, expected to fare better due to strong domestic chronic therapy exposure and the successful export launch of oral semaglutide in South Africa and Brazil. Cipla Limited and Lupin Ltd have cautious reads; Cipla faces margin or volume headwinds, while Lupin faces pressure from US sales softening on tolvaptan and lenalidomide erosion. Ajanta Pharma Limited and Ipca Laboratories Ltd have constructive reads, benefiting from strong chronic therapy tailwinds and stable domestic performance, respectively.

Oil and Gas Refining and Marketing > Petroleum and Petroleum Products

In the oil and gas sector, the research notes received today present a mixed to constructive read. Singapore gross refining margins remain elevated above $10/bbl on a September basis, showing a flat trend. However, Indian Oil Marketing Companies (OMCs) are facing deep marketing losses, recorded at Rs -14/litre on petrol and Rs -27/litre on diesel. This disparity highlights the lag in cost pass-through mechanisms despite favorable global refining conditions.

The data points cited indicate that Brent crude price is at $102/bbl as of October 7, 2026, with a rising trend. US crude inventories fell by 2.09 mb for the week ended October 2. The notes project that Indian OMCs face a sustained three-year refining margin upswing driven by regional capacity tightness and steady domestic demand. This is supported by the EIA raising its Q4 2026 Brent forecast to $105/bbl. Chinese product export bans through October are tightening diesel markets, while Russian diesel export bans through October 31 limit supply. Global commercial oil reserves are noted to be at dangerously low levels, increasing fragility to supply shocks.

The risks and catalysts for this sector are heavily influenced by geopolitical factors and operational constraints. SPR stocks are near their operational minimum of 250-300 mb, limiting buffer capacity. Upstream producers face near-term margin pressure from volatile crude prices. Reliance Industries Ltd has a cautious read, with O2C margins squeezed by elevated naphtha costs driven by Brent near $102/bbl and the ongoing Chinese product export ban. ONGC has a constructive read, with upstream E&P seeing positive realization direction due to high Brent prices and a deepwater gas ceiling at $9.89/MMBtu. IOCL has a cautious read due to strongly negative net impact from OMC marketing losses. MGL and BPCL have neutral reads based on routine regulatory filings. GAIL (India) Ltd is in active discussions to acquire up to a 26% minority stake in a US LNG export project tied to a 15-year import deal of 1 MMTPA starting 2029-2030.

While domestic pharma sales grow at 17% YoY, export-oriented players face margin compression from freight costs surging 93% year-on-year.

What to Watch

Investors should monitor the Commerce department review on reshoring 86 essential generics scheduled for April 2027, which could impact US generic exports. Additionally, watch for updates on the Chinese and Russian diesel export bans through October, which are currently tightening global supply. For listed companies, keep an eye on the resolution of GAIL's discussions regarding the US LNG stake acquisition and any further developments in the White House budget office review related to Section 232 tariffs.

---

Published by FinBizNet Desk. This article is market data and research for educational purposes only; it is not investment advice, a recommendation, or a solicitation to transact. FinBizNet is not a SEBI-registered investment advisor. Please consult a registered advisor before making investment decisions.